Capital Investment Advisors LLC Buys 93 Shares of Becton, Dickinson and Company (NYSE:BDX)

Capital Investment Advisors LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,030 shares of the medical instruments supplier’s stock after purchasing an additional 93 shares during the quarter. Capital Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $465,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BDX. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $25,000. Sierra Ocean LLC bought a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. REAP Financial Group LLC boosted its stake in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 55 shares during the last quarter. Picton Mahoney Asset Management boosted its stake in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 54 shares during the last quarter. Finally, Nexus Investment Management ULC bought a new position in Becton, Dickinson and Company in the first quarter valued at approximately $34,000. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on BDX shares. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Raymond James cut shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Bank of America cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price objective for the company. in a research report on Thursday, May 1st. Morgan Stanley lowered their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Finally, Citigroup cut shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and lowered their price objective for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $219.22.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Richard Byrd sold 459 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the transaction, the executive vice president now directly owns 6,952 shares in the company, valued at $1,598,960. The trade was a 6.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president now owns 4,575 shares in the company, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,104 shares of company stock worth $399,675. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.0%

BDX opened at $174.21 on Wednesday. The stock has a market capitalization of $49.93 billion, a P/E ratio of 28.94, a P/E/G ratio of 1.63 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm’s fifty day simple moving average is $184.92 and its 200 day simple moving average is $214.07. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The business had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the previous year, the firm posted $3.17 EPS. The firm’s revenue was up 4.5% compared to the same quarter last year. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be paid a $1.04 dividend. The ex-dividend date is Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.39%. Becton, Dickinson and Company’s payout ratio is currently 79.39%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.